Alpa laboratories has announced a key management appointment, naming Ms. Yashoda Patidar as the company's new Company Secretary and Compliance Officer. The appointment was formalized during a Board of Directors meeting held on April 11, 2026, and takes effect immediately from the same date.

Board Approval and Regulatory Compliance

The appointment received approval from the Board of Directors based on recommendations from the Nomination and Remuneration Committee. The company has notified both the Bombay Stock Exchange and National Stock Exchange of India about this appointment in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Appointee Profile and Qualifications

Ms. Yashoda Patidar brings professional expertise to her new role as an Associate Member of the Institute of Company Secretaries of India. Her credentials include:

Key Appointment Details

The appointment follows standard corporate governance practices, with the company confirming that Ms. Patidar holds no shareholding in Alpa Laboratories Ltd. The disclosure indicates no relationship between the appointee and existing directors of the company.

Corporate Communication

The formal intimation was signed by Director Mahendra Singh Chawla (DIN: 00362058) and communicated to both stock exchanges where the company's shares are listed. This appointment strengthens the company's compliance framework and corporate governance structure as Ms. Patidar assumes responsibility for ensuring adherence to regulatory requirements and secretarial functions.

Alpa laboratories has issued a clarification to stock exchanges regarding recent price movement in its shares, confirming that there is no undisclosed price sensitive information affecting the company's performance.

Stock Exchange Communication

In response to an inquiry dated April 8, 2026, from stock exchanges regarding price movement in the company's stock, Alpa Laboratories submitted its clarification on April 9, 2026. The communication was addressed to both the Bombay Stock Exchange and National Stock Exchange of India Ltd.

Company's Clarification

The pharmaceutical company stated that there is no information or event that would have a bearing on the company's performance, confirming that no price sensitive information has been withheld from disclosure. Director Mahendra Singh Chawla emphasized that the company does not have any announcement in the near future which may impact the price or volume of its scrip.

Regulatory Compliance

The clarification was issued under Regulation 30 of securities regulations, which requires listed companies to disclose material events and information that could affect stock prices. The company's proactive response demonstrates adherence to disclosure norms and transparency requirements for listed entities.

The communication serves to address any market speculation regarding the stock's price movement and reaffirms the company's commitment to timely disclosure of material information to investors and regulatory authorities.